With its latest trial readout for under-the-skin efgartigimod, argenx is adding another feather to the FcRn blocker’s cap.  | ...

AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso ...

With a massive array of prescription drugs losing patent protection in the coming years, including many biologics, Sandoz has ...

The pharmaceutical industry creates some of the most valuable products in human history: Medicines that can extend, save and better our lives. | The pharmaceutical industry creates some of the most ...

With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the ...

With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives and other government measures with the potential to hit pr | ...

A federal appeals court has overturned (PDF) the 2024 dismissal of a lawsuit filed by Celgene shareholders that accuses Bristol Myers Squibb of slow-walking the approval of blood cancer drug Breyanzi ...

With the European Union formally reversing its marketing authorization for the rare disease med Tavneos last week, regulators from the bloc are laying out their concerns about the data backing the ...

More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's interim CEO, Alan Bash ...

In a historic breakthrough for targeted protein degradation, Bristol Myers Squibb has secured the first FDA approval for a CELMoD therapy, with clearance of Zenbexus (iberdomide) as part of a ...

AstraZeneca’s newly approved, first-in-class hypertension drug Baxfendy does not clear the bar for effectiveness relative to its price, according to the Institute for Clinical and Economic Review ( | ...

In a deal announced this week, Alfasigma spent an undisclosed sum to continue its global expansion in immunology.  | Alfasigma will add key drugs like Nordimet through the deal, as well as Nordic ...